A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma
/in Dendritic Cells, Endometrial Cancer, International Publications /von 2021-11-18 / Cancers (Basel) 2021 Nov;13(22)Prognostic Factors for Endometrial and Cervical Cancers of Uterus Treated With Immune-cell Therapy: A Retrospective Study
/in Cervical Cancer, Dendritic Cells, Endometrial Cancer, International Publications /von 2020-08-01 / Anticancer Res 2020 Aug;40(8):4729-4740[The effect of immunotherapy and hyperthermia on advanced or recurrent ovarian and uterine cancer – 229 clinical cases]
/in Endometrial Cancer, International Publications, Ovarian Cancer /von 2014-10-01 / Gan To Kagaku Ryoho 2014 Oct;41(10):1295-7Dendritic cell immunotherapy in uterine cancer
/in Dendritic Cells, Endometrial Cancer, International Publications /von 2014-01-01 / Hum Vaccin Immunother 2014;10(7):1822-7Wilms‘ Tumor Gene 1 (WT1)–loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial
/in Dendritic Cells, Endometrial Cancer, International Publications /von 2013-12-01 / Anticancer Res 2013 Dec;33(12):5495-500Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma
/in Dendritic Cells, Endometrial Cancer, International Publications /von 2010-09-01 / Anticancer Res 2010 Sep;30(9):3709-14Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial
/in Dendritic Cells, Endometrial Cancer, International Publications, Ovarian Cancer /von 2002-01-10 / Cancer Immunol. Immunother. 2002 Mar;51(1):45-52Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer
/in Dendritic Cells, Endometrial Cancer, International Publications, Ovarian Cancer /von 2002-01-07 / Br. J. Cancer 2002 Jan;86(1):151-7IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de